Cargando…

Gemcitabine Plus Platinum versus Docetaxel Plus Platinum as First-Line Therapy for Metastatic Nasopharyngeal Carcinoma: A Randomized Clinical Study

BACKGROUND: A well-established first-line chemotherapy standard for metastatic nasopharyngeal carcinoma is yet lacking. OBJECTIVES: To compare the efficacy and safety of gemcitabine plus platinum versus docetaxel plus platinum regimen as first-line therapies for distal metastatic nasopharyngeal carc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Hui, Lu, Ying, Xu, Zhuohua, Wei, Mingjing, Huang, Haixin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152382/ https://www.ncbi.nlm.nih.gov/pubmed/34084103 http://dx.doi.org/10.4103/sjmms.sjmms_471_20

Ejemplares similares

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)
por: Rosenberg, Jonathan E., et al.
Publicado: (2018)

Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma
por: Zhu, Yunshu, et al.
Publicado: (2020)

Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma by Targeting the Epidermal Growth Factor Receptor Combined with Gemcitabine Plus Platinum
por: Chen, Chen, et al.
Publicado: (2020)

Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma
por: Sun, Xue-Song, et al.
Publicado: (2020)

Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
por: Grande, Enrique, et al.
Publicado: (2023)

Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study
por: Salimon, Maëva, et al.
Publicado: (2018)

Gemcitabine Plus Vinorelbine as Second-Line Therapy in Patients With Metastatic Esophageal Cancer Previously Treated With Platinum-Based Chemotherapy
por: Wang, Yue-shen, et al.
Publicado: (2016)

Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)
por: Necchi, Andrea, et al.
Publicado: (2020)

Comparison of Efficacy and Safety of Taxanes Plus Platinum and Fluorouracil Plus Platinum in the First-Line Treatment of Esophageal Cancer: A Systematic Review and Meta-Analysis
por: Zhao, Yue, et al.
Publicado: (2022)

Clinical efficacy of combination therapy of an immune checkpoint inhibitor with taxane plus platinum versus an immune checkpoint inhibitor with fluorouracil plus platinum in the first-line treatment of patients with locally advanced, metastatic, or recurrent esophageal squamous cell carcinoma
por: Li, Ying, et al.
Publicado: (2022)

Treatment and Survival Outcomes Associated With Platinum Plus Low-Dose, Long-term Fluorouracil for Metastatic Nasopharyngeal Carcinoma
por: Zheng, Shuo-Han, et al.
Publicado: (2021)

Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer
por: Passildas‐Jahanmohan, Judith, et al.
Publicado: (2021)

First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis
por: Zhang, Longfeng, et al.
Publicado: (2020)

Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
por: Liu, Zhiyong, et al.
Publicado: (2022)

Platinum Plus Tegafur–Uracil versus Platinum Alone during Concurrent Chemoradiotherapy in Patients with Nonmetastatic Nasopharyngeal Carcinoma: A Propensity-Score-Matching Analysis
por: Lien, Ching-Feng, et al.
Publicado: (2022)

Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin
por: Zeng, Zhen, et al.
Publicado: (2018)

Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis
por: Liu, Xiaoyan, et al.
Publicado: (2022)

Combination chemotherapy with taxane and platinum in patients with salivary gland carcinoma: a retrospective study of docetaxel plus cisplatin and paclitaxel plus carboplatin
por: Onaga, Ryutaro, et al.
Publicado: (2023)

Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer
por: Gamucci, T, et al.
Publicado: (2007)

Comparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer
por: Shi, Yafei, et al.
Publicado: (2023)

Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study
por: Hong, Shaodong, et al.
Publicado: (2021)

Prognostic value of early radiological response to first‐line platinum‐containing chemotherapy in patients with metastatic nasopharyngeal carcinoma
por: Liu, Guo‐Ying, et al.
Publicado: (2019)

A randomized, double‐blind, phase II study of oral histone deacetylase inhibitor resminostat plus S‐1 versus placebo plus S‐1 in biliary tract cancers previously treated with gemcitabine plus platinum‐based chemotherapy
por: Ueno, Makoto, et al.
Publicado: (2021)

Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer
por: Cappuzzo, F, et al.
Publicado: (2004)

The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial
por: Tang, Lin-Quan, et al.
Publicado: (2023)

Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine
por: Di Costanzo, Francesco, et al.
Publicado: (2023)

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
por: Yardley, D A, et al.
Publicado: (2018)

An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer
por: Cavalieri, Stefano, et al.
Publicado: (2022)

Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China
por: Liu, Huiqin, et al.
Publicado: (2022)

Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: an open-label phase 2 study
por: Lu, Nian, et al.
Publicado: (2023)

Complete remission of platinum-refractory primary Fallopian tube carcinoma with third-line gemcitabine plus cisplatin: A case report and review of the literature
por: XU, QIUYI, et al.
Publicado: (2013)

The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC)
por: Yang, Jiaying, et al.
Publicado: (2016)

A comparison of neoadjuvant chemotherapy with gemcitabine versus docetaxel plus cisplatin in locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis
por: Liu, Tongxin, et al.
Publicado: (2018)

Correction: Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China
por: Liu, Huiqin, et al.
Publicado: (2023)

Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck
por: Mesía, R., et al.
Publicado: (2010)

Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab‐paclitaxel as first‐line chemotherapy for advanced pancreatic adenocarcinoma: A single‐center retrospective analysis
por: Schlick, Konstantin, et al.
Publicado: (2023)

Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment
por: li, Meiying, et al.
Publicado: (2015)

Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
por: Stemmler, H J, et al.
Publicado: (2011)

Gemcitabine plus S-1 for metastatic pancreatic cancer
por: Zhu, Hong, et al.
Publicado: (2018)

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer
por: Wist, E. A., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_8u5rmc0el771l3ebctqhpra675